

# Menno V Huisman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7862372/publications.pdf>

Version: 2024-02-01

272  
papers

31,140  
citations

25034

57  
h-index

4645

170  
g-index

292  
all docs

292  
docs citations

292  
times ranked

26954  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2016, 149, 315-352.	0.8	4,060
2	Incidence of thrombotic complications in critically ill ICU patients with COVID-19. <i>Thrombosis Research</i> , 2020, 191, 145-147.	1.7	3,872
3	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	2.2	2,591
4	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	2.2	2,426
5	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	27.0	1,419
6	Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. <i>Thrombosis Research</i> , 2020, 191, 148-150.	1.7	1,357
7	Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. <i>New England Journal of Medicine</i> , 2008, 358, 2765-2775.	27.0	1,349
8	Effectiveness of Managing Suspected Pulmonary Embolism Using an Algorithm Combining Clinical Probability, D-Dimer Testing, and Computed Tomography. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 172.	7.4	935
9	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Respiratory Journal</i> , 2019, 54, 1901647.	6.7	806
10	Age-Adjusted D-Dimer Cutoff Levels to Rule Out Pulmonary Embolism. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1117.	7.4	680
11	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1599-1607.	27.0	658
12	Right Ventricular Dysfunction and Pulmonary Obstruction Index at Helical CT: Prediction of Clinical Outcome during 3-month Follow-up in Patients with Acute Pulmonary Embolism. <i>Radiology</i> , 2005, 235, 798-803.	7.3	453
13	Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. <i>Lancet, The</i> , 2017, 390, 289-297.	13.7	357
14	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2021, 160, e545-e608.	0.8	357
15	Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. <i>European Respiratory Journal</i> , 2017, 49, 1601792.	6.7	339
16	Unexpected High Prevalence of Silent Pulmonary Embolism in Patients with Deep Venous Thrombosis. <i>Chest</i> , 1989, 95, 498-502.	0.8	335
17	The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. <i>Blood Reviews</i> , 2014, 28, 221-226.	5.7	296
18	Simplification of the Revised Geneva Score for Assessing Clinical Probability of Pulmonary Embolism. <i>Archives of Internal Medicine</i> , 2008, 168, 2131.	3.8	255

#	ARTICLE	IF	CITATIONS
19	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	2.8	244
20	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
21	Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. <i>Haematologica</i> , 2010, 95, 970-975.	3.5	220
22	Resolution of Thromboemboli in Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2006, 129, 192-197.	0.8	215
23	Performance of 4 Clinical Decision Rules in the Diagnostic Management of Acute Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2011, 154, 709.	3.9	211
24	Pulmonary embolism. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18028.	30.5	208
25	Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. <i>Thrombosis and Haemostasis</i> , 2012, 107, 838-847.	3.4	201
26	Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2019, 380, 1139-1149.	27.0	200
27	Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. <i>BMJ: British Medical Journal</i> , 2017, 356, j1065.	2.3	174
28	Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?. <i>Thrombosis Research</i> , 2020, 193, 86-89.	1.7	156
29	Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 134-144.	6.7	152
30	Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. <i>Blood</i> , 2013, 122, 1144-1149.	1.4	146
31	Patient Outcomes after Acute Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 501-506.	5.6	138
32	Quality of Life in Long-term Survivors of Acute Pulmonary Embolism. <i>Chest</i> , 2010, 138, 1432-1440.	0.8	136
33	Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. <i>American Journal of Medicine</i> , 2015, 128, 1306-1313.e1.	1.5	135
34	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	3.4	132
35	Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1874-1882.	3.8	122
36	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1668-1678.	3.4	121

#	ARTICLE	IF	CITATIONS
37	Wells Rule and D-Dimer Testing to Rule Out Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2016, 165, 253.	3.9	119
38	Vaccine-induced immune thrombotic thrombocytopenia. <i>Lancet Haematology</i> , 2022, 9, e73-e80.	4.6	114
39	Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>American Heart Journal</i> , 2014, 167, 329-334.	2.7	112
40	Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-BNP Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 998-1006.	5.6	107
41	Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. <i>Thrombosis Research</i> , 2021, 199, 143-148.	1.7	98
42	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1128-1136.	3.4	93
43	Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism. <i>Respiratory Medicine</i> , 2010, 104, 1744-1749.	2.9	92
44	Residual venous thrombosis as predictive factor for recurrent venous thromboembolism in patients with proximal deep vein thrombosis: a systematic review. <i>British Journal of Haematology</i> , 2011, 153, 168-178.	2.5	85
45	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2376-2388.	3.4	84
46	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 183-189.	2.2	83
47	Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. <i>European Respiratory Journal</i> , 2015, 45, 201-210.	6.7	82
48	Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis. <i>Blood</i> , 2014, 124, 623-627.	1.4	81
49	Safety of excluding acute pulmonary embolism based on an unlikely clinical probability by the Wells rule and normal D-dimer concentration: A meta-analysis. <i>Thrombosis Research</i> , 2010, 125, e123-e127.	1.7	77
50	Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 652-660.	2.2	76
51	A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. <i>Thrombosis Research</i> , 2011, 128, 21-26.	1.7	76
52	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. <i>PLoS ONE</i> , 2015, 10, e0122520.	2.5	69
53	How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. <i>Blood</i> , 2020, 135, 724-734.	1.4	66
54	Atrial fibrillation and cancer – An unexplored field in cardiovascular oncology. <i>Blood Reviews</i> , 2019, 35, 59-67.	5.7	64

#	ARTICLE	IF	CITATIONS
55	Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. <i>European Heart Journal</i> , 2021, 42, 3146-3157.	2.2	64
56	Time-Dependent Effects of Aspirin on Blood Pressure and Morning Platelet Reactivity. <i>Hypertension</i> , 2015, 65, 743-750.	2.7	62
57	Macrophage Low-Density Lipoprotein Receptor-Related Protein Deficiency Enhances Atherosclerosis in ApoE/LDLR Double Knockout Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2710-2715.	2.4	61
58	A Clinical Prognostic Model for the Identification of Low-Risk Patients With Acute Symptomatic Pulmonary Embolism and Active Cancer. <i>Chest</i> , 2013, 143, 138-145.	0.8	58
59	Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2011, 6, 521-528.	2.0	56
60	How I diagnose acute pulmonary embolism. <i>Blood</i> , 2013, 121, 4443-4448.	1.4	56
61	Computed tomography pulmonary angiography versus ventilation-perfusion lung scanning for diagnosing pulmonary embolism during pregnancy: a systematic review and meta-analysis. <i>Haematologica</i> , 2019, 104, 176-188.	3.5	56
62	Partial protein S gene deletion in a family with hereditary thrombophilia. <i>Blood</i> , 1989, 73, 479-483.	1.4	55
63	Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, 4186-4195.	2.2	55
64	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 616-624.	3.4	55
65	Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. <i>Europace</i> , 2016, 18, 1308-1318.	1.7	54
66	Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 731-738.	0.6	54
67	D-dimer Testing in Patients with Suspected Pulmonary Embolism and Impaired Renal Function. <i>American Journal of Medicine</i> , 2009, 122, 1050-1053.	1.5	52
68	Simple and safe exclusion of pulmonary embolism in outpatients using quantitative D-dimer and Wells's simplified decision rule. <i>Thrombosis and Haemostasis</i> , 2007, 97, 146-150.	3.4	51
69	Measurement of Right and Left Ventricular Function by ECG-Synchronized CT Scanning in Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2011, 140, 1008-1015.	0.8	50
70	External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>Thrombosis Research</i> , 2015, 135, 796-801.	1.7	50
71	Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. <i>Rheumatology</i> , 2017, 56, 1676-1683.	1.9	50
72	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020, 41, 1132-1140.	2.2	50

#	ARTICLE	IF	CITATIONS
73	Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 412-420.	2.3	47
74	To screen or not to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>Thrombosis Research</i> , 2017, 151, 1-7.	1.7	45
75	Diagnostic management of clinically suspected acute pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 312-317.	3.8	44
76	Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale. <i>Thrombosis Research</i> , 2020, 190, 45-51.	1.7	44
77	Management of incidental pulmonary embolism. <i>European Respiratory Journal</i> , 2017, 49, 1700275.	6.7	43
78	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. <i>Thorax</i> , 2021, 76, 1002-1009.	5.6	41
79	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	5.8	40
80	Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. <i>American Journal of Medicine</i> , 2017, 130, 135-145.	1.5	40
81	Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. <i>American Heart Journal</i> , 2018, 198, 55-63.	2.7	40
82	Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1573-1583.	2.8	39
83	Effect of No Prehydration vs Sodium Bicarbonate Prehydration Prior to Contrast-Enhanced Computed Tomography in the Prevention of Postcontrast Acute Kidney Injury in Adults With Chronic Kidney Disease. <i>JAMA Internal Medicine</i> , 2020, 180, 533.	5.1	39
84	Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. <i>Blood</i> , 2020, 135, 1377-1385.	1.4	39
85	Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer. <i>Chest</i> , 2016, 149, 1245-1251.	0.8	38
86	Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. <i>European Journal of Cancer</i> , 2021, 148, 371-381.	2.8	38
87	Impact of Delay in Clinical Presentation on the Diagnostic Management and Prognosis of Patients with Suspected Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1369-1373.	5.6	37
88	Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. <i>Circulation</i> , 2019, 139, 748-756.	1.6	36
89	Anticoagulation practice patterns in COVID-19: A global survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 969-983.	2.3	35
90	Current imaging modalities for diagnosing cerebral vein thrombosis – A critical review. <i>Thrombosis Research</i> , 2020, 189, 132-139.	1.7	35

#	ARTICLE	IF	CITATIONS
91	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate- to High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 857-866.	3.4	35
92	Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease. <i>PLoS ONE</i> , 2014, 9, e94420.	2.5	35
93	Pulmonary infarction in acute pulmonary embolism. <i>Thrombosis Research</i> , 2021, 202, 162-169.	1.7	34
94	Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis. <i>Thorax</i> , 2018, 73, 464-471.	5.6	33
95	Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis. <i>Critical Care Medicine</i> , 2021, 49, e1025-e1036.	0.9	33
96	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. <i>Annals of Internal Medicine</i> , 2022, 175, 29-35.	3.9	33
97	The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off increases the number of patients in whom acute pulmonary embolism can safely be excluded. <i>Thrombosis and Haemostasis</i> , 2012, 107, 167-171.	3.4	32
98	Pharmacological properties of betrixaban. <i>European Heart Journal Supplements</i> , 2018, 20, E12-E15.	0.1	32
99	Performance of idarucizumab as antidote of dabigatran in daily clinical practice. <i>Europace</i> , 2019, 21, 414-420.	1.7	31
100	Diagnostic outcome management study in patients with clinically suspected recurrent acute pulmonary embolism with a structured algorithm. <i>Thrombosis Research</i> , 2014, 133, 1039-1044.	1.7	30
101	Accuracy and reproducibility of CT right-to-left ventricular diameter measurement in patients with acute pulmonary embolism. <i>PLoS ONE</i> , 2017, 12, e0188862.	2.5	28
102	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1277.	7.4	28
103	Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. <i>American Journal of Medicine</i> , 2018, 131, 945-955.e3.	1.5	27
104	Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups. <i>Annals of Internal Medicine</i> , 2022, 175, 244-255.	3.9	27
105	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 646-656.	3.4	25
106	Computed tomography pulmonary angiography as a single imaging test to rule out pulmonary embolism. <i>Current Opinion in Pulmonary Medicine</i> , 2011, 17, 380-386.	2.6	24
107	Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome. <i>Thrombosis Research</i> , 2021, 206, 66-75.	1.7	24
108	Current challenges in diagnostic imaging of venous thromboembolism. <i>Blood</i> , 2015, 126, 2376-2382.	1.4	23

#	ARTICLE	IF	CITATIONS
109	Reliability of diagnosing incidental pulmonary embolism in cancer patients. <i>Thrombosis Research</i> , 2015, 136, 531-534.	1.7	22
110	Computerised clinical decision support for suspected PE: Table 1. <i>Thorax</i> , 2015, 70, 909-911.	5.6	22
111	Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 363-372.	1.5	22
112	Determinants and Management of the Post-Pulmonary Embolism Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 299-307.	2.1	22
113	Prophylaxis and treatment of COVID-19 related venous thromboembolism. <i>Postgraduate Medicine</i> , 2021, 133, 27-35.	2.0	22
114	Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. <i>PLoS ONE</i> , 2019, 14, e0222658.	2.5	21
115	Lower prevalence of subsegmental pulmonary embolism after application of the YEARS diagnostic algorithm. <i>British Journal of Haematology</i> , 2018, 183, 629-635.	2.5	20
116	Management and treatment of deep vein thrombosis in special populations. <i>Expert Review of Hematology</i> , 2018, 11, 685-695.	2.2	20
117	Performance of a diagnostic algorithm based on a prediction rule, D-dimer and CT-scan for pulmonary embolism in patients with previous venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 113, 406-413.	3.4	19
118	Stroke prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. <i>Clinical Cardiology</i> , 2018, 41, 744-751.	1.8	19
119	Antithrombotic therapy after mitral valve repair: VKA or aspirin?. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 473-481.	2.1	19
120	Post-thrombotic syndrome: Short and long-term incidence and risk factors. <i>Thrombosis Research</i> , 2019, 177, 102-109.	1.7	19
121	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Haematologica</i> , 2020, 105, 1436-1442.	3.5	19
122	Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. <i>American Journal of Cardiology</i> , 2020, 125, 383-391.	1.6	19
123	Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. <i>Journal of Arrhythmia</i> , 2021, 37, 990-1006.	1.2	19
124	Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 92-103.	3.8	19
125	Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis. <i>PLoS Medicine</i> , 2022, 19, e1003905.	8.4	19
126	Clinically suspected acute recurrent pulmonary embolism: A diagnostic challenge. <i>Thrombosis and Haemostasis</i> , 2007, 97, 944-948.	3.4	18



#	ARTICLE	IF	CITATIONS
127	Pitfalls in the diagnostic management of pulmonary embolism in pregnancy. <i>Thrombosis Research</i> , 2017, 151, S86-S91.	1.7	18
128	Clinical effects of antiplatelet drugs and statins on D-dimer levels. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12944.	3.4	18
129	Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program. <i>American Heart Journal</i> , 2019, 218, 123-127.	2.7	18
130	Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1251-1261.	2.3	18
131	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2751-2759.	3.8	18
132	Prediction of chronic thromboembolic pulmonary hypertension with standardised evaluation of initial computed tomography pulmonary angiography performed for suspected acute pulmonary embolism. <i>European Radiology</i> , 2022, 32, 2178-2187.	4.5	18
133	Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1622-1629.	3.4	17
134	Sensitivity of a Simple Noninvasive Screening Algorithm for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. <i>TH Open</i> , 2018, 02, e89-e95.	1.4	17
135	The physician's estimation of alternative diagnosis is less likely than pulmonary embolism in the Wells rule is dependent on the presence of other required items. <i>Thrombosis and Haemostasis</i> , 2008, 99, 244-245.	3.4	16
136	Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. <i>Haematologica</i> , 2015, 100, 188-193.	3.5	16
137	Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. <i>American Journal of Emergency Medicine</i> , 2016, 34, 46-51.	1.6	16
138	Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. <i>European Respiratory Review</i> , 2018, 27, 180094.	7.1	16
139	&lt;p&gt;When to withhold oral anticoagulation in atrial fibrillation – an overview of frequent clinical discussion topics&lt;/p&gt;. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 399-408.	2.3	16
140	Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 248-256.	0.6	16
141	Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 58, 2100699.	6.7	16
142	Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1665-1673.	3.8	16
143	Recurrent venous thromboembolism: diagnosis and management. <i>Current Opinion in Pulmonary Medicine</i> , 2000, 6, 330-334.	2.6	15
144	Treating Patients with Venous Thromboembolism: Initial Strategies and Long-Term Secondary Prevention. <i>Seminars in Vascular Medicine</i> , 2005, 5, 276-284.	2.1	15

#	ARTICLE	IF	CITATIONS
145	Advances in the diagnosis and management of acute pulmonary embolism. <i>Thrombosis Research</i> , 2014, 133, S10-S16.	1.7	15
146	Identification of chronic thromboembolic pulmonary hypertension on CTPAs performed for diagnosing acute pulmonary embolism depending on level of expertise. <i>European Journal of Internal Medicine</i> , 2021, 93, 64-70.	2.2	15
147	Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 560-573.	3.3	15
148	Diagnosing upper extremity deep vein thrombosis with non-contrast-enhanced Magnetic Resonance Direct Thrombus Imaging: A pilot study. <i>Thrombosis Research</i> , 2018, 163, 47-50.	1.7	14
149	Diagnosis of recurrent venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 229-235.	1.7	14
150	A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. <i>ERJ Open Research</i> , 2021, 7, 00719-2020.	2.6	14
151	Clinical Surveillance vs. Anticoagulation For low-risk patients with isolated Subsegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE). <i>BMJ Open</i> , 2020, 10, e040151.	1.9	13
152	Direct Oral Anticoagulants Are a Potential Alternative to Low-Molecular-Weight Heparin for Thromboprophylaxis in Trauma Patients Sustaining Lower Extremity Fractures. <i>Journal of Surgical Research</i> , 2021, 258, 324-331.	1.6	13
153	Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. <i>American Journal of Medicine</i> , 2016, 129, S89-S96.	1.5	12
154	Performance of the age-adjusted cut-off for D-dimer in patients with cancer and suspected pulmonary embolism. <i>Thrombosis Research</i> , 2017, 152, 49-51.	1.7	12
155	Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e032488.	1.9	12
156	Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1390-1397.	3.8	12
157	Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients. <i>Postgraduate Medicine</i> , 2021, 133, 36-41.	2.0	12
158	Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial. <i>Blood</i> , 2007, 110, 6-6.	1.4	12
159	Persistence with Dabigatran Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Gloria-AF Registry. <i>Blood</i> , 2016, 128, 2616-2616.	1.4	12
160	Randomized trial of one-hour sodium bicarbonate vs standard periprocedural saline hydration in chronic kidney disease patients undergoing cardiovascular contrast procedures. <i>PLoS ONE</i> , 2018, 13, e0189372.	2.5	12
161	Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e023907.	3.7	12
162	Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 548-559.	3.3	12

#	ARTICLE	IF	CITATIONS
163	Seeking optimal treatment for phlegmasia cerulea dolens. <i>Thrombosis Research</i> , 2013, 131, 372-373.	1.7	11
164	Optimization of the diagnostic management of clinically suspected pulmonary embolism in hospitalized patients. <i>British Journal of Haematology</i> , 2014, 167, 681-686.	2.5	11
165	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. <i>Pharmacological Research</i> , 2015, 94, 1-8.	7.1	11
166	Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis. <i>Thrombosis Research</i> , 2017, 154, 64-72.	1.7	11
167	Home treatment of patients with cancer-associated venous thromboembolism – An evaluation of daily practice. <i>Thrombosis Research</i> , 2019, 184, 122-128.	1.7	11
168	Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry. <i>Journal of Arrhythmia</i> , 2020, 36, 408-416.	1.2	11
169	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. <i>Journal of Clinical Medicine</i> , 2020, 9, 1969.	2.4	11
170	Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients: A multicenter case-control study. <i>Thrombosis Research</i> , 2021, 200, 87-90.	1.7	11
171	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> , 2021, 8, e627-e636.	4.6	11
172	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. <i>European Journal of Cancer</i> , 2022, 165, 136-145.	2.8	11
173	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic) Tj ETQq1 1 0,784314 rgrBT /Oveldo	1.7	10
174	Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. <i>Europace</i> , 2019, 22, 47-57.	1.7	10
175	Diagnostic management of acute pulmonary embolism in special populations. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 729-736.	2.5	10
176	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	3.8	10
177	Why, Whom, and How to Screen for Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 692-701.	2.7	10
178	Pulmonary flow profile and distensibility following acute pulmonary embolism. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2011, 13, 14.	3.3	9
179	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2425-2434.	3.4	9
180	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. <i>Clinical Cardiology</i> , 2019, 42, 346-351.	1.8	9

#	ARTICLE	IF	CITATIONS
181	Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. <i>European Journal of Internal Medicine</i> , 2020, 80, 35-44.	2.2	9
182	Uncertain Value of High-sensitive Troponin T for Selecting Patients With Acute Pulmonary Embolism for Outpatient Treatment by Hestia Criteria. <i>Academic Emergency Medicine</i> , 2020, 27, 1043-1046.	1.8	9
183	Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. <i>PLoS ONE</i> , 2020, 15, e0232354.	2.5	9
184	Patients With Atrial Fibrillation and a CHA2DS2-VASc Score of 1. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1395-1397.	2.8	8
185	Aortic Arch Stiffness Is Associated With Incipient Brain Injury in Patients With Hypertension. <i>American Journal of Hypertension</i> , 2016, 29, 705-712.	2.0	8
186	Higher Adherence to Treatment With Low-molecular-weight Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-associated Venous Thromboembolism. <i>HemaSphere</i> , 2018, 2, e19.	2.7	8
187	Validation and impact of a simplified clinical decision rule for diagnosing pulmonary embolism in primary care: design of the PECAN prospective diagnostic cohort management study. <i>BMJ Open</i> , 2019, 9, e031639.	1.9	8
188	Safety of using the combination of the Wells rule and D-dimer test for excluding acute recurrent ipsilateral deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2341-2348.	3.8	8
189	Accurate diagnosis of iliac vein thrombosis in pregnancy with magnetic resonance direct thrombus imaging (MRDTI). <i>BMJ Case Reports</i> , 2016, 2016, bcr2016218091.	0.5	8
190	Dabigatran Is Associated with a Significantly Lower Risk of Abnormal Uterine Bleeding Than Warfarin in Female Patients of Childbearing Age with Venous Thromboembolism. <i>Blood</i> , 2016, 128, 140-140.	1.4	8
191	Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 1057-1068.	3.3	8
192	Post-Pulmonary Embolism Syndrome and Functional Outcomes after Acute Pulmonary Embolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 848-860.	2.7	8
193	Recovery of right and left ventricular function after acute pulmonary embolism. <i>Clinical Radiology</i> , 2011, 66, 1203-1207.	1.1	7
194	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD study. <i>Journal of Medical Economics</i> , 2017, 20, 435-442.	2.1	7
195	Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>BMJ Open</i> , 2020, 10, e036220.	1.9	7
196	Current practice patterns of outpatient management of acute pulmonary embolism: A post-hoc analysis of the YEARS study. <i>Thrombosis Research</i> , 2020, 193, 60-65.	1.7	7
197	Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF. <i>ESC Heart Failure</i> , 2020, 7, 2679-2689.	3.1	7
198	Ruling out Pulmonary Embolism in Patients with (Suspected) COVID-19: A Prospective Cohort Study. <i>TH Open</i> , 2021, 05, e387-e399.	1.4	7

#	ARTICLE	IF	CITATIONS
199	Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.. Blood, 2005, 106, 280-280.	1.4	7
200	Evaluation of the new simple and objective clinical decision rule "DVT" in patients with clinically suspected acute deep vein thrombosis. Thrombosis Research, 2016, 141, 112-118.	1.7	6
201	Clinical outcome of patients with a vitamin K antagonist-associated bleeding treated with prothrombin complex concentrate. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 77-84.	2.3	6
202	Diagnosing Recurrent DVT of the Leg by Two Different Non-Contrast-Enhanced Magnetic Resonance Direct Thrombus Imaging Techniques: A Pilot Study. TH Open, 2019, 03, e37-e44.	1.4	6
203	Magnetic Resonance Thrombus Imaging to Differentiate Acute from Chronic Portal Vein Thrombosis. TH Open, 2020, 04, e224-e230.	1.4	6
204	Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS ONE, 2021, 16, e0249524.	2.5	6
205	Diagnostic accuracy of four different D-dimer assays: A post-hoc analysis of the YEARS study. Thrombosis Research, 2021, 201, 18-22.	1.7	6
206	When I treat a patient with acute pulmonary embolism at home. Hematology American Society of Hematology Education Program, 2020, 2020, 190-194.	2.5	6
207	Accuracy of Magnetic Resonance Direct Thrombus Imaging (MRDTI) As a Novel Tool in the Diagnosis of Acute Ipsilateral Recurrent Deep Vein Thrombosis. Blood, 2012, 120, 395-395.	1.4	6
208	Current challenges in diagnostic imaging of venous thromboembolism. Hematology American Society of Hematology Education Program, 2015, 2015, 202-209.	2.5	5
209	Diclofenac for reversal of right ventricular dysfunction in acute normotensive pulmonary embolism: A pilot study. Thrombosis Research, 2018, 162, 1-6.	1.7	5
210	Persistence to direct oral anticoagulants for acute venous thromboembolism. Thrombosis Research, 2018, 167, 135-141.	1.7	5
211	Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score. Heart, 2021, 107, 549-555.	2.9	5
212	Detection of upper extremity deep vein thrombosis by magnetic resonance non-contrast thrombus imaging. Journal of Thrombosis and Haemostasis, 2021, 19, 1973-1980.	3.8	5
213	Performance of the revised Geneva score in patients with a delayed suspicion of pulmonary embolism. European Respiratory Journal, 2014, 43, 1801-1804.	6.7	4
214	The Newer Anticoagulants in Thrombosis Control in Cancer Patients. Seminars in Oncology, 2014, 41, 339-345.	2.2	4
215	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. Thrombosis Research, 2018, 163, 128-131.	1.7	4
216	Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice. Seminars in Interventional Radiology, 2018, 35, 83-91.	0.8	4

#	ARTICLE	IF	CITATIONS
217	Occurrence of Antithrombotic Related Adverse Events in Hospitalized Patients: Incidence and Clinical Context between 2008 and 2016. <i>Journal of Clinical Medicine</i> , 2019, 8, 839.	2.4	4
218	Chest X-Ray Not Routinely Indicated Prior to the YEARS Algorithm in the Diagnostic Management of Suspected Pulmonary Embolism. <i>TH Open</i> , 2019, 03, e22-e27.	1.4	4
219	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	2.8	4
220	Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1027-1036.	1.9	4
221	Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program. <i>IJC Heart and Vasculature</i> , 2021, 34, 100763.	1.1	4
222	Diagnostic Management of Acute Pulmonary Embolism in COVID-19 and Other Special Patient Populations. <i>Diagnostics</i> , 2022, 12, 1350.	2.6	4
223	The proof for new oral anticoagulants: clinical trial evidence. <i>European Orthopaedics and Traumatology</i> , 2011, 2, 7-14.	0.1	3
224	Reply to C.L. O'Connell et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 4209-4210.	1.6	3
225	The Diagnostic Management of Recurrent Deep Vein Thrombosis and Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 151-155.	2.1	3
226	Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2163-2167.	3.4	3
227	How reliable is perioperative anticoagulant management? Determining guideline compliance and practice variation by a retrospective patient record review. <i>BMJ Open</i> , 2019, 9, e029879.	1.9	3
228	Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice. <i>TH Open</i> , 2020, 04, e119-e126.	1.4	3
229	The prognostic value of ECG-derived ventricular gradient in early adverse events in acute pulmonary embolism patients. <i>Thrombosis Update</i> , 2021, 2, 100033.	0.9	3
230	Computed tomography pulmonary perfusion imaging and 3-months clinical outcomes after acute pulmonary embolism. <i>Thrombosis Research</i> , 2021, 199, 32-34.	1.7	3
231	Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis. <i>Blood Advances</i> , 2021, 5, 1369-1378.	5.2	3
232	Home Treatment Compared to Initial Hospitalization in Normotensive Patients with Acute Pulmonary Embolism in the Netherlands: A Cost Analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 427-433.	3.4	3
233	Magnetic Resonance Direct Thrombus Imaging (MRDTI) Can Distinguish Between Old and New Thrombosis in the Abdominal Aorta: a Case Report. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 7, 001351.	0.4	3
234	Partial protein S gene deletion in a family with hereditary thrombophilia. <i>Blood</i> , 1989, 73, 479-483.	1.4	3

#	ARTICLE	IF	CITATIONS
235	Treatment of venous thromboembolism: duration and new options. <i>The Hematology Journal</i> , 2004, 5, S24-S28.	1.4	2
236	Is pulmonary embolism associated with reactive mediastinal and hilar lymphadenopathy?. <i>Thrombosis Research</i> , 2010, 125, 557-558.	1.7	2
237	Deep Venous Thrombosis and Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 125-126.	2.1	2
238	Reasons for Hospitalization of Patients with Acute Pulmonary Embolism Based on the Hestia Decision Rule. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1217-1220.	3.4	2
239	Lack of diagnostic utility of the ECG-derived ventricular gradient in patients with suspected acute pulmonary embolism. <i>Journal of Electrocardiology</i> , 2020, 61, 141-146.	0.9	2
240	Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry. <i>IJC Heart and Vasculature</i> , 2020, 31, 100666.	1.1	2
241	Anticoagulant selection in relation to the SAME-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 152-157.	1.0	2
242	Computed Tomography Pulmonary Perfusion for Prediction of Short-Term Clinical Outcome in Acute Pulmonary Embolism. <i>TH Open</i> , 2021, 05, e66-e72.	1.4	2
243	Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism. <i>Blood</i> , 2019, 134, 2429-2429.	1.4	2
244	Prevalence, risk factors, and long-term outcomes of cerebral ischemia in hospitalized COVID-19 patients – study rationale and protocol of the CORONIS study: A multicentre prospective cohort study. <i>European Stroke Journal</i> , 0, , 239698732210925.	5.5	2
245	First do no harm. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12694.	2.3	2
246	Arterial indications for the low molecular weight heparins. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001, 2, 233.	1.5	1
247	Dabigatran-related coagulopathy: when can we assume the effect has ‘‘worn off’’. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1433-1434.	1.6	1
248	Therapeutic management of acute pulmonary embolism. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 641-648.	2.5	1
249	Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1371-1378.	1.9	1
250	How can we better predict pulmonary blood clots in patients hospitalised for COVID-19?. <i>European Respiratory Journal</i> , 2020, 56, 2003092.	6.7	1
251	Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF. <i>TH Open</i> , 2021, 05, e35-e42.	1.4	1
252	Magnetic resonance thrombus imaging for the differentiation of chronic versus (sub)acute cerebral vein thrombosis: A case report. <i>Thrombosis Update</i> , 2021, 2, 100039.	0.9	1

#	ARTICLE	IF	CITATIONS
253	Toward a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1834-1835.	3.8	1
254	Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. <i>European Journal of Internal Medicine</i> , 2021, 91, 75-80.	2.2	1
255	Clinical trial results – A closer look under the surface. <i>European Journal of Internal Medicine</i> , 2020, 75, 21-22.	2.2	1
256	Unequal prescription of anticoagulants among females and males with atrial fibrillation and similar stroke risk: Should we omit sex category from the CHA2DS2-VASc score?. <i>Heart Rhythm</i> , 2022, 19, 860-861.	0.7	1
257	Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program. <i>Medicina Clínica</i> , 2021, , .	0.6	1
258	Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	1
259	Imaging Tests for Suspected Deep Vein Thrombosis. <i>JAMA Internal Medicine</i> , 2015, 175, 1873.	5.1	0
260	Letter to the Editor. <i>Journal of Intensive Care Medicine</i> , 2016, 31, 70-71.	2.8	0
261	P1618 Lower prevalence of isolated subsegmental pulmonary embolism in the YEARS diagnostic algorithm compared with the conventional algorithm for suspected pulmonary embolism. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
262	Duration of anticoagulant treatment for unprovoked deep-vein thrombosis – is prolonged long enough?. <i>Haematologica</i> , 2019, 104, 1300-1301.	3.5	0
263	Direct oral anticoagulants and obesity: one size fits all?. <i>Lancet Haematology</i> , the, 2019, 6, e341-e342.	4.6	0
264	Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'. <i>British Journal of Cancer</i> , 2019, 120, 472-472.	6.4	0
265	Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. <i>Thrombosis Research</i> , 2020, 196, 404-409.	1.7	0
266	Outpatient Treatment In Patients with Acute Pulmonary Embolism: The Hestia Study. <i>Blood</i> , 2010, 116, LBA-1-LBA-1.	1.4	0
267	Age-Adjusted D-Dimer Cut-off Levels to Rule out Pulmonary Embolism: A Prospective Outcome Study. <i>Blood</i> , 2013, 122, LBA-4-LBA-4.	1.4	0
268	The Performance of the Original and Simplified Wells Scores in Combination with Age-Adjusted D-Dimer Testing in the Diagnostic Management of Pulmonary Embolism. <i>Blood</i> , 2016, 128, 2569-2569.	1.4	0
269	Safety and Efficiency of the YEARS Diagnostic Algorithm for Pregnant Patients with Clinically Suspected Acute Pulmonary Embolism – the Artemis Study. <i>Blood</i> , 2018, 132, 419-419.	1.4	0
270	Differential effect of anticoagulant treatment on vascular morphology in patients with acute pulmonary embolism. <i>European Heart Journal</i> , 2020, 41, .	2.2	0



#	ARTICLE	IF	CITATIONS
271	Accurate and efficient non-invasive strategy for early identification of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism (InShape II study). <i>European Heart Journal</i> , 2020, 41, .	2.2	0
272	Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia. <i>European Journal of Haematology</i> , 2022, 108, 310-318.	2.2	0